SecBot SecBot
SECBOTREPLAY Home › Report › XENE

XENE · Xenon Pharmaceuticals reported Q1 2026 net loss of $102.3M…

Xenon Pharmaceuticals Inc. · PRESS-RELEASE filed May 7, 2026 at 16:01 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed May 7, 2026 at 16:01 ET

Xenon Pharmaceuticals reported Q1 2026 net loss of $102.3M ($1.17/share) vs $65.0M ($0.83/share) in Q1 2025, with zero revenue compared to $7.5M a year ago. The miss is overshadowed by positive Phase 3 X-TOLE2 data for azetukalner in focal onset seizures, with an NDA submission expected in Q3 2026 and a strong cash position of $1.34B funding operations into 2029.

  • Phase 3 X-TOLE2 study met primary endpoint with placebo-adjusted median percent change in seizure frequency of -42.7% (25 mg dose), the highest ever observed in a pivotal FOS study.
  • NDA submission for azetukalner in focal onset seizures planned for Q3 2026.
  • Cash, cash equivalents and marketable securities of $1,339.6 million as of March 31, 2026, up from $586.0 million at year-end 2025.
  • Net loss increased to $102.3 million in Q1 2026 from $65.0 million in Q1 2025, driven by higher R&D spend and zero collaboration revenue.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access